BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Zeng QL, Zhang JY, Zhang Z, Wang LF, Wang FS. Sofosbuvir and ABT-450: Terminator of hepatitis C virus? World J Gastroenterol 2013; 19(21): 3199-3206 [PMID: 23745021 DOI: 10.3748/wjg.v19.i21.3199]
URL: https://www.wjgnet.com/1007-9327/full/v19/i21/3199.htm
Number Citing Articles
1
Anupriya S. Kulkarni, Masad J. Damha, Raymond F. Schinazi, Hongmei Mo, Brian Doehle, Selena M. Sagan, Matthias Götte. A Complex Network of Interactions between S282 and G283 of Hepatitis C Virus Nonstructural Protein 5B and the Template Strand Affects Susceptibility to Sofosbuvir and RibavirinAntimicrobial Agents and Chemotherapy 2016; 60(4): 2018 doi: 10.1128/AAC.02436-15
2
Komal Saleem, Braira Wahid, Amjad Ali, Shazia Rafique, Zara Naz, Sana Usman, Muhammad Idrees. Unexpected Response Profiles Seen in Hepatitis C Virus-Infected Patients Treated with Sofosbuvir Plus Ribavirin: Five Case ReportsViral Immunology 2018; 31(6): 480 doi: 10.1089/vim.2017.0199
3
Qing-Lei Zeng, Guang-Hua Xu, Ji-Yuan Zhang, Wei Li, Da-Wei Zhang, Zhi-Qin Li, Hong-Xia Liang, Chun-Xia Li, Zu-Jiang Yu. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational studyJournal of Hepatology 2017; 66(6): 1123 doi: 10.1016/j.jhep.2017.01.025
4
Tingting Tao, Xuehua Jiang, Yuehong Chen, Yiran Song. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysisInternational Journal of Infectious Diseases 2017; 55: 56 doi: 10.1016/j.ijid.2016.12.023
5
Jesús Ruiz Ramos, Irene Romero Hernández, Patricia Marrero Álvarez, María Remedios Marqués Miñana, María José Fernández Megía, José Luis Poveda Andrés. Experiencia en el manejo de inmunosupresores con los fármacos inhibidores de proteasa frente al virus de la hepatitis CGastroenterología y Hepatología 2014; 37(10): 558 doi: 10.1016/j.gastrohep.2014.05.004
6
Yu-Ming Lee, Yulander Duh, Shih-Ting Wang, Michael M.C. Lai, Hanna S. Yuan, Carmay Lim. Using an Old Drug to Target a New Drug Site: Application of Disulfiram to Target the Zn-Site in HCV NS5A ProteinJournal of the American Chemical Society 2016; 138(11): 3856 doi: 10.1021/jacs.6b00299
7
Andres F Carrion, Julio Gutierrez, Paul Martin. New antiviral agents for the treatment of hepatitis C: ABT-450Expert Opinion on Pharmacotherapy 2014; 15(5): 711 doi: 10.1517/14656566.2014.889116
8
Dan-Dan He, Wei-Zhe Li, Shuo Huang, Li-Ping Zhang, Jing-Jing Li, Zhao-Hai Zeng, Zu-Jiang Yu, Qing-Lei Zeng. HBsAg Loss Due to Tenofovir Treatment for HBV Reactivation Following DAAs Therapy in One Patient with HBV-HCV CoinfectionInfectious Diseases & Immunity 2021; 1(2): 115 doi: 10.1097/ID9.0000000000000009
9
Qing-Lei Zeng, Zhi-Qin Li, Hong-Xia Liang, Guang-Hua Xu, Chun-Xia Li, Da-Wei Zhang, Wei Li, Chang-Yu Sun, Fu-Sheng Wang, Zu-Jiang Yu. Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: Too alarming?Journal of Hepatology 2016; 65(5): 1068 doi: 10.1016/j.jhep.2016.07.029
10
Yongzhi Chen, Shanshan Wang, Zhaohong Yi, Huabin Tian, Roghiyh Aliyari, Yanhua Li, Gang Chen, Ping Liu, Jin Zhong, Xinwen Chen, Peishuang Du, Lishan Su, F. Xiao-Feng Qin, Hongyu Deng, Genhong Cheng. Interferon-Inducible Cholesterol-25-Hydroxylase Inhibits Hepatitis C Virus Replication via Distinct MechanismsScientific Reports 2014; 4(1) doi: 10.1038/srep07242
11
Hye Jin Yang, Ju Yeon Ryoo, Bong Kyu Yoo. Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infectionInternational Journal of Clinical Pharmacy 2015; 37(5): 698 doi: 10.1007/s11096-015-0144-x
12
Fatma Abdallah, Gehad Mohamed, Mohsen Ibrahim, Mokhtar El Tarabily. Effectiveness of Sofosbuvir, Ribavirin and PEG-IFNα-2a in the Treatment of Naïve Egyptian Patients With Chronic Hepatitis C Virus Genotype 4The American Journal of the Medical Sciences 2018; 355(5): 456 doi: 10.1016/j.amjms.2017.12.016
13
Dong-Hoon Chung, Jennifer E. Golden, Robert S. Adcock, Chad E. Schroeder, Yong-Kyu Chu, Julie B. Sotsky, Daniel E. Cramer, Paula M. Chilton, Chisu Song, Manu Anantpadma, Robert A. Davey, Aminul I. Prodhan, Xinmin Yin, Xiang Zhang. Discovery of a Broad-Spectrum Antiviral Compound That Inhibits Pyrimidine Biosynthesis and Establishes a Type 1 Interferon-Independent Antiviral StateAntimicrobial Agents and Chemotherapy 2016; 60(8): 4552 doi: 10.1128/AAC.00282-16
14
Clara C. Posthuma, Aartjan J.W. te Velthuis, Eric J. Snijder. Nidovirus RNA polymerases: Complex enzymes handling exceptional RNA genomesVirus Research 2017; 234: 58 doi: 10.1016/j.virusres.2017.01.023
15
Q.‐L. Zeng, C.‐X. Li, D.‐W. Zhang, W. Li, G.‐H. Xu, Z.‐J. Yu. Letter: safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12 weeks in Chinese treatment‐experienced cirrhotic genotype 1b patients with HCVAlimentary Pharmacology & Therapeutics 2016; 43(7): 842 doi: 10.1111/apt.13541
16
Igor Bakulin, Victor Pasechnikov, Anna Varlamicheva, Irina Sannikova. NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safetyWorld Journal of Hepatology 2014; 6(5): 326-339 doi: 10.4254/wjh.v6.i5.326
17
Mansuri Reema, Patel Dhara, Patel Khushboo, Meshram Dhananjay. In depth investigation of quantitative analytical and bioanalytical techniques of hepatitic drug sofosbuvir in different matrices: a reviewJournal of Analytical & Pharmaceutical Research 2018; 7(2) doi: 10.15406/japlr.2018.07.00228